argenx announces results of Annual General Meeting of Shareholders

argenx announces results of Annual General Meeting of Shareholders

Written by Customer Service on . Posted in Public Companies.

May 7, 2024 – 5:30pm ET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today.

All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy).

As part of the approved resolutions:

  • The Company’s annual report and annual accounts for the financial year ending December 31, 2023 were approved;
  • Dr. Brian L. Kotzin has been appointed as non-executive director to the Board of Directors for a term of four years. Dr. Kotzin brings broad medical and scientific research and development experience to the Board, supporting the Company’s innovation mission across therapeutic areas.
  • Peter Verhaeghe and Dr. Pamela Klein have been re-appointed as non-executive directors to the Board of Directors for a term of 2 years;
  • The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights;
  • An amendment of the articles of association of the Company was approved
  • Deloitte Accountants B.V. has been appointed as the Company’s auditor for the 2024 financial year; and
  • Ernst & Young Accountants LLP has been appointed as the Company’s auditor for the 2025 financial year.

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and UK, and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com/ and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:
Ben Petok
Bpetok@argenx.com

Investors:
Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.